William Blair Forecasts Alector’s Q1 Earnings (NASDAQ:ALEC)

Alector, Inc. (NASDAQ:ALEC) – Equities research analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Alector in a research note issued to investors on Thursday, February 27th. William Blair analyst M. Minter expects that the company will post earnings of ($0.54) per share for the quarter. The consensus estimate for Alector’s current full-year earnings is ($1.88) per share. William Blair also issued estimates for Alector’s Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.54) EPS and Q4 2026 earnings at ($0.52) EPS.

Alector (NASDAQ:ALEC) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.59. The firm had revenue of $54.24 million for the quarter, compared to the consensus estimate of $20.41 million. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%.

Other equities analysts also recently issued research reports about the company. BTIG Research cut their target price on Alector from $16.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, November 26th. Mizuho lowered Alector from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $9.00 to $2.50 in a report on Tuesday, December 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Alector in a research note on Tuesday, November 26th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Alector in a research report on Thursday. Finally, Stifel Nicolaus downgraded shares of Alector from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a report on Monday, December 16th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $3.75.

Alector Stock Performance

Alector stock opened at $1.64 on Friday. Alector has a fifty-two week low of $1.55 and a fifty-two week high of $7.57. The firm’s 50-day simple moving average is $1.78 and its 200 day simple moving average is $3.53. The stock has a market cap of $160.61 million, a PE ratio of -0.96 and a beta of 0.61.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC bought a new position in shares of Alector in the fourth quarter worth $25,000. Tema Etfs LLC bought a new position in Alector in the 4th quarter worth about $27,000. Tower Research Capital LLC TRC boosted its stake in Alector by 71.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 14,670 shares of the company’s stock worth $28,000 after purchasing an additional 6,096 shares during the period. Point72 DIFC Ltd purchased a new position in Alector during the 3rd quarter valued at about $29,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Alector during the third quarter valued at about $40,000. 85.83% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Sara Kenkare-Mitra sold 26,500 shares of Alector stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $2.52, for a total value of $66,780.00. Following the completion of the transaction, the insider now owns 565,215 shares in the company, valued at $1,424,341.80. This trade represents a 4.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Arnon Rosenthal sold 52,172 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $2.52, for a total transaction of $131,473.44. Following the completion of the sale, the chief executive officer now directly owns 2,507,074 shares in the company, valued at approximately $6,317,826.48. This trade represents a 2.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 95,161 shares of company stock valued at $239,806 in the last 90 days. Insiders own 9.10% of the company’s stock.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.